Can Fite Biopharma Analyst Price Targets

Wall Street analyst price targets and consensus rating for Can Fite Biopharma (CANF).

Price Target Range — 10 Quarters

Analyst Consensus — 3 Analysts

3Buy

Consensus RatingBuy# Analysts3Avg. Consensus PT$144Upside to Avg. PT+7587.2%

Rating Trend — Last 9 Months

Recent Analyst Actions

Ver todas las valoraciones →

Date	Firm	Analyst	Action	Rating Change	Price Target
Jul 2, 2026	HC Wainwright & Co.	Swayampakula Ramakanth	PT Raise	Buy	$5→$8
May 13, 2026	D. Boral Capital	Jason Kolbert	Upgrade	Hold→Buy	$7
May 12, 2026	HC Wainwright & Co.	Swayampakula Ramakanth	PT Raise	Buy	$3→$5
Dec 24, 2025	D. Boral Capital	Jason Kolbert	Downgrade	Buy→Hold	—
Dec 17, 2025	D. Boral Capital	Jason Kolbert	PT Cut	Buy	$11→$4
Nov 18, 2025	D. Boral Capital	Jason Kolbert	Maintained	Buy	$11
Nov 4, 2025	HC Wainwright & Co.	Swayampakula Ramakanth	Assumes	Buy	$3
Sep 16, 2025	D. Boral Capital	Jason Kolbert	Maintained	Buy	$11
Sep 2, 2025	D. Boral Capital	Jason Kolbert	Maintained	Buy	$11
Jul 29, 2025	D. Boral Capital	Jason Kolbert	Maintained	Buy	$10
Apr 15, 2025	D. Boral Capital	Jason Kolbert	Maintained	Buy	$10
Mar 21, 2025	D. Boral Capital	Jason Kolbert	Maintained	Buy	$10
Mar 20, 2025	D. Boral Capital	Jason Kolbert	Maintained	Buy	$10
Mar 18, 2025	D. Boral Capital	Jason Kolbert	Maintained	Buy	$10
Mar 3, 2025	D. Boral Capital	Jason Kolbert	Maintained	Buy	$10
Feb 18, 2025	D. Boral Capital	Jason Kolbert	Maintained	Buy	$10
Dec 31, 2024	D. Boral Capital	Jason Kolbert	Maintained	Buy	$10
Dec 5, 2024	D. Boral Capital	Jason Kolbert	Maintained	Buy	$10
Nov 12, 2024	HC Wainwright & Co.	Vernon Bernardino	Maintained	Buy	$18
Oct 10, 2024	EF Hutton	Jason Kolbert	Maintained	Buy	$10

More with Benzinga EdgeGet Access

Analyst Ratings News

PRO
HC Wainwright & Co. Reiterates Buy on Can Fite Biopharma, Raises Price Target to $8

HC Wainwright & Co. analyst Swayampakula Ramakanth reiterates Can Fite Biopharma (AMEX:CANF) with a Buy and raises the price target from $5 to $8.

Benzinga Newsdesk

PRO
D. Boral Capital Upgrades Can Fite Biopharma to Buy, Announces $7 Price Target

D. Boral Capital analyst Jason Kolbert upgrades Can Fite Biopharma (AMEX:CANF) from Hold to Buy and announces $7 price target.

Benzinga Newsdesk

PRO
HC Wainwright & Co. Maintains Buy on Can Fite Biopharma, Raises Price Target to $5

HC Wainwright & Co. analyst Swayampakula Ramakanth maintains Can Fite Biopharma (AMEX:CANF) with a Buy and raises the price target from $2.5 to $5.

Benzinga Newsdesk

PRO
D. Boral Capital Maintains Buy on Can Fite Biofarma, Lowers Price Target to $4

D. Boral Capital analyst Jason Kolbert maintains Can Fite Biofarma (AMEX:CANF) with a Buy and lowers the price target from $11 to $4.

Benzinga Newsdesk

PRO
D. Boral Capital Maintains Buy on Can Fite Biofarma, Maintains $11 Price Target

D. Boral Capital analyst Jason Kolbert maintains Can Fite Biofarma (AMEX:CANF) with a Buy and maintains $11 price target.

Benzinga Newsdesk

PRO
HC Wainwright & Co. Assumes Can Fite Biofarma at Buy, Announces Price Target of $2.5

HC Wainwright & Co. analyst Swayampakula Ramakanth assumes Can Fite Biofarma (AMEX:CANF) with a Buy rating and announces Price Target of $2.5.

Benzinga Newsdesk

Can Fite Biopharma Ltd

Noticias

SOCIO/CONTRIBUIDOR

BENZINGA GLOBAL

Can Fite Biopharma Analyst Price Targets

Recent Analyst Actions

Analyst Ratings News

PRO
HC Wainwright & Co. Reiterates Buy on Can Fite Biopharma, Raises Price Target to $8

PRO
D. Boral Capital Upgrades Can Fite Biopharma to Buy, Announces $7 Price Target

PRO
HC Wainwright & Co. Maintains Buy on Can Fite Biopharma, Raises Price Target to $5

PRO
D. Boral Capital Maintains Buy on Can Fite Biofarma, Lowers Price Target to $4

PRO
D. Boral Capital Maintains Buy on Can Fite Biofarma, Maintains $11 Price Target

PRO
HC Wainwright & Co. Assumes Can Fite Biofarma at Buy, Announces Price Target of $2.5

People Also Watch

People Also Watch

Can Fite Biopharma Ltd

Noticias

SOCIO/CONTRIBUIDOR

BENZINGA GLOBAL

Can Fite Biopharma Analyst Price Targets

Recent Analyst Actions

Analyst Ratings News

PROHC Wainwright & Co. Reiterates Buy on Can Fite Biopharma, Raises Price Target to $8

PROD. Boral Capital Upgrades Can Fite Biopharma to Buy, Announces $7 Price Target

PROHC Wainwright & Co. Maintains Buy on Can Fite Biopharma, Raises Price Target to $5

PROD. Boral Capital Maintains Buy on Can Fite Biofarma, Lowers Price Target to $4

PROD. Boral Capital Maintains Buy on Can Fite Biofarma, Maintains $11 Price Target

PROHC Wainwright & Co. Assumes Can Fite Biofarma at Buy, Announces Price Target of $2.5

People Also Watch

People Also Watch

PRO
HC Wainwright & Co. Reiterates Buy on Can Fite Biopharma, Raises Price Target to $8

PRO
D. Boral Capital Upgrades Can Fite Biopharma to Buy, Announces $7 Price Target

PRO
HC Wainwright & Co. Maintains Buy on Can Fite Biopharma, Raises Price Target to $5

PRO
D. Boral Capital Maintains Buy on Can Fite Biofarma, Lowers Price Target to $4

PRO
D. Boral Capital Maintains Buy on Can Fite Biofarma, Maintains $11 Price Target

PRO
HC Wainwright & Co. Assumes Can Fite Biofarma at Buy, Announces Price Target of $2.5